Identify patient at risk for Candida infection Major risk factors includeOther risk factors include Previous bacterial infection and therapy Tunneled venous.

Slides:



Advertisements
Similar presentations
NOSOCOMIAL ANTIBIOTIC RESISTANT ORGANISMS
Advertisements

GOOD MORNING! Thursday, February 2, CSF Shunts Used in the setting of hydrocephalus to divert CSF to another part of the body for absorption Proximal.
From Guidelines to Bedside: Clinical Case Scenario Approach Mazen Kherallah, MD, FCCP.
Candidiasis C. Charunee 9/4/50.
The Evolution of Fungal Infections in the Surgical Patient
Fungal Infection in the ICU
Initial Antifungal Therapy for Critical Ill Patients When and Which ? 林口長庚 胸腔內科 林鴻銓 Lin, Horng-Chyuan Division of Pulmonary Infectious & Immunological.
URINARY TRACT INFECTION
Clinical Scenario  A 42 year old white female was admitted to the hospital with hematemesis and melena. The patient had a history of cirrhosis with ascites.
Pelvic inflammatory disease
Urinary Tract Infection
Ois generalPCPCryptococcus-Toxoplasma
Empiric Antifungal Therapy in the ICU
Pam Charity, MD Cathryn Caton, MD, MS.  Define pneumonia  Review criteria for diagnosis  Review criteria for admission  Review treatment options.
Management of Clostridium difficile Infections
Rex summary of updated IDSA Candidiasis guidelines.ppt IDSA Candidiasis Guidelines John H. Rex, MD Adjunct Professor of Medicine; University of Texas.
QUESTIONS AND ANSWERS. A patient is admitted to the surveillance specialty with a catheter in situ Are they included in CAUTI surveillance?
Treatment of urinary tract infections
Fungal Infections Who is at Risk Seriously ill patients being treated with Corticosteroids Antineoplastic drugs Immunosuppressive drugs Patients with.
MRSA and VRE. MRSA  1974 – MRSA accounted for only 2% of total staph infections  1995 – MRSA accounted for 22% of total staph infections  2004 – MRSA.
MRSA and VRE. MRSA  1974 – MRSA accounted for only ____of total staph infections  1995 – MRSA accounted for _____ of total staph infections  2004 –
Prof.Hanan Habib. To eradicate the offending organisms from the urinary bladder and tissues. The main treatment of UTI is by antibiotics.
Lecturer name: Dr. Ahmed M. Al-Barrag Lecture Date:
Candida Fungemia Risks and Therapy Hail M. Al-Abdely, M.D. Associate Consultant King Faisal Specialist Hospital.
A primary or secondary mycotic infection caused by members of the genus Candida. The clinical manifestations may be acute, subacute or chronic to episodic.
Antibiotic overuse and misuse in long term care Shira Doron, MD Assistant Professor of Medicine Division of Geographic Medicine and Infectious Diseases.
M_MAHMOUDIEH General Surgeon Department of Surgery.
Approach to Catheter-related Bloodstream Infections in Patients on Haemodialysis Nephrology discussion Registrar: Dr. Coetser Consultants: Prof. Van Rensburg.
Fungus: SICU Bradley J. Phillips, M.D. Burn-Trauma-ICU Adults & Pediatrics.
Treatment of urinary tract infections Prof. Hanan Habib.
AbstractAbstract IntroductionIntroduction MethodsMethods ResultsResults Candida albicans accounted for 45.2%, Candida tropicalis 22.3%, Candida glabrata.
Which drugs?. Mode of action of antifungals ergosterol polyenes e.g. amphotericin B polyenes azoles e.g. fluconazole azoles nucleosides e.g. 5-flucytosine.
CANDIDIASIS Endocrine block March 2014 Dr. Ahmed Al-Barrag Asst. Professor of Medical Mycology School of Medicine and the University Hospitals King Saud.
Flucoral capsules Product knowledge. Pharmacokinetics of fluconazole Distribution of Fluconazole is extensive and even throughout tissues. The high polarity.
Antimicrobial treatment for Systemic Candidiasis.
OPPORTUNISTIC MYCOSES
Respiratory Fungal Infections-II Dr. Ahmed Al-Barrag Asst. Professor of Medical Mycology School of Medicine and the University Hospitals King Saud University.
BIBLE PAPER 26 AUG 2015 CANDIDA GLABRATA ESOPHAGITIS: ARE WE SEEING THE EMERGENCE OF A NEW AZOLE-RESISTANT PATHOGEN? WILSON A, DELPORT J, PONICH T. INT.
Treatment of urinary tract infections
Pharmacodynamics of Antifungals
Nosocomial infection Hospital acquired infections.
ANTIFUNGAL DRUGS PHARM 514 Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington
Managing Candidemia JEANNE FORRESTER, PHARMD, BCPS PGY2 INFECTIOUS DISEASES PHARMACY RESIDENT MEDICAL UNIVERSITY OF SOUTH CAROLINA.
Fungal endophthalmitis
1. Candida 의 항진균제 감수성과 항진균제 간의 교차내성 2. Disseminated candidiasis 의 치료 약제 선택 3. Refractory case 에서의 치료 약제 선택.
Candidiasis A primary or secondary mycotic infection caused by members of the genus Candida. The clinical manifestations may be acute, subacute or chronic.
La terapia antifungina nel paziente critico Francesco Menichetti, MD Head, Infectious Diseases Unit Ospedale Nuovo Santa Chiara Pisa, Italy SIMIT 2015.
Candidiasis Downloded from
Pyogenic Liver Abscess 소화기내과 R4 신아리 MGR Disease Review.
Risk Factors for Candida dubliniensis Bloodstream Infections Katherine Veltman, B.S., Peggy L. Carver, Pharm.D, FCCP The University of Michigan Health.
MANAGEMENT OF NEUTROPENIC FEVERS IN CANCER PATIENTS Jerry Yu.
Medicine II Homework January 6, 2010 Subsection B4 Facilitator: Remedios F. Coronel, M.D.
Fungal infection of urinary tract 신장내과 R4 최선영. Opportunistic fungal pathogen in urinary tract  Candida : most prevalent and pathogenic fungi UTI –hematogenous.
Fungal Peritonitis (FP) Constantinos J. Stefanidis “P. and A. Kyriakou” Children’s Hospital Athens, Greece.
Nosocomial Antibiotic Resistant Organisms
Lecture Title: Fungal Infections of Central Nervous System
Candidiasis Endocrine block.
Therapeutics 3: Antibiotics Tutoring
Candidiasis Endocrine block.
Management of Urinary Tract Infections Renal Block
Management of Urinary Tract Infections Renal Block
Universidad Militar Nueva Granada, School of Medicine
NOSOCOMIAL ANTIBIOTIC RESISTANT ORGANISMS
Staten Island University Hospital, Staten Island, New York, USA
This slide set is meant to be used as an adjunct resource to the Medscape program titled “Managing Invasive Candidiasis: A Systematic Approach” by Thomas.
Intra-Abdominal Candidiasis, Candida peritonitis
بنام خداوند جان و خرد بنام خداوند جان و خرد.
Efficacy of Chromogenic Candida Agar for isolation and presumptive identification of pathogenic yeast species  E. Ghelardi, G. Pichierri, B. Castagna,
Pharmacokinetic/Pharmacodynamic Dosing
Presentation transcript:

Identify patient at risk for Candida infection Major risk factors includeOther risk factors include Previous bacterial infection and therapy Tunneled venous catheters with multiple antibiotics Urinary catheters Isolation of Candida from > 2 sites Diarrhea Immunosuppression Parenteral nutrition Hemodialysis Mechanical ventilation Previous surgical procedures Prolonged ICU stay (eg, deep abdominal or cardiac) Malignancies Extensive burns or severe trauma Initiate studies to diagnose candidiasis Obtain cultures from oropharynx, sputum, stool, urine, drain sites, and blood Obtain two sets of blood cultures for 2 days (or longer if the patient remains febrile) Consider serologic tests and histologic analyses Look for findings that may signal hematogenous candidiasis Endophthalmitis Suppurative thrombophlebitis High-grade candiduria without instrumentation of the bladder or the renal pelvis Colonization with Candida at > 2 sites (>1 site for C tropicalis) Exclude other possible causes of persistent fever Blood culture positive Blood cultures are positive for Candida, or clinical or laboratory signal of potential hematogenous candidiasis is present Blood culture negative-Candida isolated >2 sites Blood cultures are negative for Candida, and no clinical or laboratory signal of potential hematogenous candidiasis is present, but Candida is isolated from >2 remote sites (>1 site for C tropicalis) Give 400 mg. IV/day fluconazole until clinical evidence of response to treatment, then 400 mg/day po unless patient condition precludes reliable oral therapy. If patient is colonized by C krusel, C glabrata, or C lusitaniae, give amphotericin B, 0.5 mg/kg/day. (Consider adding flucytosine, 25 mg/kg/day po in two divided doses, for C glabrata and C lusitaniae.) Treat for 7 to 10 days (patient should be free of signs and symptoms of infection for 5 days before treatment is ended). Blood culture negative-Candida isolated <1 site Blood cultures are negative for Candida, no clinical or laboratory signal of potential hematogenous candidiasis is found, and Candida is isolated from <1 remote sites (0 sites for C tropicalis) Continue surveillance cultures weekly. See next page

Blood culture positive for fungal infection or deep organ infection Organisms not identified Initiate presumptive therapy Hemodynamically stable Patient is hemodynamically stable, does not have high-grade candidemia, and does not appear to have organ infection. Remove all venous catheters Hemodynamically unstable Patient is hemodynamically unstable, has high-grade candidemia, or shows evidence of organ infection Remove all venous catheters Treat any associated sydromes of hematogenous candidiasis (eg, endophthalmitis, pericarditis, suppurative thrombophlebitis, endocarditis). Patient is infected or colonized by C albicans, C tropicalis, C parapsilosis Give 400 mg IV/day fluconazole until clinical evidence of response to treatment, then 400 mg/day po unless patient condition precludes reliable oral therapy Treat for 7 to 10 days (patient should be free of signs and symptoms of infection for 5 days before treatment is needed). Patient is infected or colonized by C krusei, C glabrata, or C lusitaniae Give amphotericia B, 0.5 to 0.7 mg/kg/day. (Consider adding flucytosine, 25 mg/kg/day po in two divided doses, for C glabrata and C lusitaniae.) Treat for 7 to 10 days (patient should be free of signs and symptoms of infection for 5 days before treatment is ended). Patient is infected or colonized by C albicans, C tropicalis, C parapsilosis, or other germ tube-positive candidal organism Give combination therapy: fluconazole, 800 mg/day IV, plus flucytosine, 25 mg/kg/day po in two divided doses. Treat for 10 to 14 days after disappearance of all signs and symptoms of infection. Patient is infected or colonized by C krusei, C glabrata, or C lusitaniae Give combination therapy: amphotericin B, 0.7 to 1.0 mg/kg/day IV, plus flucytosine, 25 mg/kg/day po in two divided doses. Treat for 10 to 14 days after disappearance of all signs and symptoms of infection. No previous or concurrent fluconazole therapy Begin treatment with fluconazole Previous or concurrent fluconazole therapy Treat with amphotericin Organism identification